Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
| Website: | www.minervaneurosciences.com |
| Email: | wboni@minervaneurosciences.com |
| Main Phone: | +1 617 600-7373 |
| Address: | 1601 Trapelo Road |
| Address 2: | Suite 286 |
| State: | MA |
| City / Town: | Waltham |
| Country: | USA |
| Postal Code: | 02451 |
| Exchange: | NSD |
| CEO: | Remy Luthringer |
| Employees: | 14 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. The company primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Targeted disorders include schizophrenia, insomnia, major depressive disorder and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
| Website: | www.minervaneurosciences.com |
| Email: | wboni@minervaneurosciences.com |
| Main Phone: | +1 617 600-7373 |
| Address: | 1601 Trapelo Road |
| Address 2: | Suite 286 |
| State: | MA |
| City / Town: | Waltham |
| Country: | USA |
| Postal Code: | 02451 |
| Exchange: | NSD |
| CEO: | Remy Luthringer |
| Employees: | 14 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 6.47 | Change $ -0.05 | Change % -0.77 | Tick N/A |
| Bid 6.32 | Bid Size 100.00 | Ask 6.99 | Ask Size 200.00 |
| Open 6.56 | High 6.56 | Low 6.40 | Prev Close 6.52 |
| Last Trade | Volume 251,297 | 52 Wk Hi 12.95 | 52 Wk Low 4.07 |
| Market Cap 252.5 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 39,025,471.00 | EPS (TTM) -1.38 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 8 |
| Number of Buys | 0 | 4 |
| Number of Sells | 0 | 4 |
| Net Activity | 0 | 32410 |
| Last 10 Buys | Shares |
|---|---|
| Marc D. Beer | 1,000 |
| Marc D. Beer | 1,000 |
| David J. Kupfer | 1,000 |
| David J. Kupfer | 1,000 |
| David J. Kupfer | 1,000 |
| Francesco De Rubertis | 1,000 |
| Michèle Ollier | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Remy Luthringer | 1,000 |
| Frederick W. Ahlholm | 1,000 |
| Joseph Reilly | 1,000 |
| Geoff Race | 1,000 |
| Mark S. Levine | 1,000 |
| Frederick W. Ahlholm | 1,000 |
| Frederick W. Ahlholm | 1,000 |
| Remy Luthringer | 1,000 |
| Geoff Race | 1,000 |
| Remy Luthringer | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 18 | 18 | 18 | 18 |
| Low Target Price Estimate | 11 | 11 | 11 | 11 |
| Mean Target Price Estimate | 14.5 | 14.5 | 14.5 | 14.5 |
| Standard Deviation | 4.95 | 4.95 | 4.95 | 4.95 |
| Date of Most Recent Estimate | 03/12/18 | 03/12/18 | 03/12/18 | 03/12/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 8-K | Report of unscheduled material events or corporate changes. | 22 | 2018-06-11 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 34 | 2018-05-03 |
| DEFA14A | Additional proxy soliciting materials - definitive | 5 | 2018-04-24 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 66 | 2018-04-24 |
| 8-K | Report of unscheduled material events or corporate changes. | 33 | 2018-03-22 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
